ReviewFrontiers in health services2026
Strengthening patient safety through biosafety and infection prevention measures during COVID-19: a policy and practice review.
Review in Frontiers in health services, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placed substantial pressure on global healthcare systems, biosafety management, and the delivery of safe clinical services. As a critical component of infection prevention and control (IPC), biosafety contributes not only to limiting pathogen exposure but also to protecting healthcare workers, maintaining reliable diagnostic pathways, and supporting patient safety and health-service continuity. This Policy and Practice Review presents a structured narrative synthesis of a sample of literature published primarily between January 2020 and August 2026, supplemented by selected earlier foundational studies and relevant public-health guidance. The review focuses on respiratory exposure control, appropriate use and oversight of personal protective equipment (PPE), airway-management safety, emergency respirator decontamination and reuse strategies including ultraviolet germicidal irradiation (UVGI), specimen collection and transport, laboratory biosafety, and emerging diagnostic technologies. The evidence indicates that safe practice requires layered, risk-based measures adapted to the exposure context and specific clinical or laboratory activity. During severe PPE shortages, UVGI was investigated as a contingency strategy for respirator decontamination, but microbial inactivation, preservation of filtration performance, and maintenance of fit or seal integrity represent distinct outcomes and require separate validation. Safe specimen pathways similarly depend on validated collection, transport, storage, and laboratory procedures that preserve both worker safety and diagnostic reliability. Emerging CRISPR- and nanomaterial-enabled technologies may improve diagnostic accessibility or turnaround time, but their contribution to patient safety depends on clinical validation, quality assurance, regulatory oversight, and successful integration into healthcare workflows. Overall, lessons from the COVID-19 pandemic support a multilayered, activity-specific approach to biosafety that integrates occupational protection, diagnostic safety, patient safety, and health-system resilience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.